生物学的安全キャビネット市場 : 2027 年までの世界予測

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2022年10月

生物学的安全キャビネット市場 : タイプ [クラス I、クラス II (タイプ A、タイプ B)、クラス III]、エンド ユーザー (製薬およびバイオ医薬品企業、診断および検査研究所、学術研究機関)、地域別 – 2027 年までの世界予測
Biological Safety Cabinet Market by Type (Class I, Class II (Type A, Type B), Class III), End User (Pharmaceutical & Biopharmaceutical Companies, Diagnostic & Testing Laboratories, Academic Research Institutes), and Region – Global Forecast to 2027

ページ数 157
図表数 140
種別 英文調査報告書
価格

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

The global biological safety cabinet market is projected to reach USD0.4billion by 2027 from USD0.2billion in 2022, at a CAGR of 8.2% during the forecast period. Market growth is driven by factors such as increased production of biosimilar products and increased research for vaccines. On the other hand, challenges associated with biological safety cabinet is alternative containment cabinets is the major factors hampering the growth of this market.

生物学的安全キャビネット市場 : タイプ [クラス I、クラス II (タイプ A、タイプ B)、クラス III]、エンド ユーザー (製薬およびバイオ医薬品企業、診断および検査研究所、学術研究機関)、地域別 - 2027 年までの世界予測
“The class II segment accounted for the highest growth rate in the biological safety cabinet market, by type, during the forecast period”
The biological safety cabinet market is segmented into class I, class II and class III. In 2021, class II segment accounted for the highest growth rate in the biological safety cabinet market. Growing pharmaceutical and biopharmaceutical industry and growing concerns over cell culture contamination are major factor contributing to the growth of this segment.
“The pharmaceutical and biopharmaceutical companies segment accounted for the highest growth rate in the biological safety cabinet market, by enduser, during the forecast period”
The biological safety cabinet market is segmented into pharmaceutical and biopharmaceutical companies, diagnostic and testing laboratories and academic research institutes based on type of waste. In 2021, the pharmaceutical and biopharmaceutical companies segment accounted for the highest growth rate in the biological safety cabinet market. Emerging markets offer lucrative growth opportunities are major factors contributing to the growth of this segment.

“Asia Pacific: The fastest-growing region in biological safety cabinet market”
The global biological safety cabinet market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Increasing number of conferences focused on creating awareness of biosafety is driving the growth of the biological safety cabinet market in this region.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 – 40%, Tier 2 – 30%,and Tier 3 -30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America -51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and the Middle East & Africa – 4%
Lists of Companies Profiled in the Report:

• Thermo Fisher Scientific (US)
• Kewaunee Scientific (US)
• Labconco (US)
• Esco Micro (Singapore)
• The Baker Company (US)
• NuAire (US)
• Germfree Laboratories (US)
• Cruma (Spain)
• Air Science (US)
• Berner International (US)
• Azbiltelstar (Spain)
• LaboGene (Denmark)
• Biolab Scientific (Canada)
• Lamsystems (Germany)
• Faster S.R.L (Italy)
• MRC Laboratory Equipment (Israel)
• Nanbei Instrument Limited (China)
• Thermolab (India)
• Labmate (UK)
• TopAir Systems, Inc. (US)
• Albian Group (Spain)
• Thomas Scientific (US)
• Zhejiang FUXIA Medical Technology Co. (China)
• Stericox (India)

生物学的安全キャビネット市場 : タイプ [クラス I、クラス II (タイプ A、タイプ B)、クラス III]、エンド ユーザー (製薬およびバイオ医薬品企業、診断および検査研究所、学術研究機関)、地域別 - 2027 年までの世界予測
Research Coverage:
This report provides a detailed picture of the global biological safety cabinetmarket. It aims at estimating the size and future growth potential of the market across different segments, such as type, end user and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall biological safety cabinet market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints and opportunities.


目次

1 INTRODUCTION 22
1.1 STUDY OBJECTIVES 22
1.2 MARKET DEFINITION 22
1.2.1 INCLUSIONS AND EXCLUSIONS 22
1.3 MARKETS COVERED 23
1.3.1 BIOLOGICAL SAFETY CABINETS MARKET SEGMENTATION 23
1.3.2 YEARS CONSIDERED 23
1.4 CURRENCY 24
1.5 LIMITATIONS 24
1.6 STAKEHOLDERS 24
1.7 SUMMARY OF CHANGES 25
2 RESEARCH METHODOLOGY 26
2.1 RESEARCH DATA 26
2.2 RESEARCH APPROACH 26
FIGURE 1 BIOLOGICAL SAFETY CABINETS MARKET: RESEARCH DESIGN 26
2.2.1 SECONDARY DATA 27
2.2.1.1 Key data from secondary sources 27
2.2.2 PRIMARY DATA 28
2.2.2.1 Primary sources 29
2.2.2.2 Key data from primary sources 29
2.2.2.3 Key industry insights 30
2.2.2.4 Breakdown of primary interviews 30
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 30
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 31
2.3 MARKET SIZE ESTIMATION 31
2.3.1 BOTTOM-UP APPROACH 32
2.3.1.1 Approach 1: Company revenue estimation approach 32
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 32
2.3.1.2 Approach 2: Presentations of companies and primary interviews 32
2.3.1.3 CAGR projections 33
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 33
2.3.2 TOP-DOWN APPROACH 33
FIGURE 6 BIOLOGICAL SAFETY CABINETS MARKET: TOP-DOWN APPROACH 33
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 34
FIGURE 7 DATA TRIANGULATION METHODOLOGY 34
2.5 MARKET SHARE ANALYSIS 35
2.6 STUDY ASSUMPTIONS 35
2.7 GROWTH RATE ASSUMPTIONS 35
2.8 RISK ASSESSMENT 36
3 EXECUTIVE SUMMARY 37
FIGURE 8 BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 37
FIGURE 9 BIOLOGICAL SAFETY CABINETS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 38
FIGURE 10 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION,
2022 VS. 2027 (USD MILLION) 38
4 PREMIUM INSIGHTS 40
4.1 BIOLOGICAL SAFETY CABINETS MARKET OVERVIEW 40
FIGURE 11 INCREASED RISK OF PANDEMICS AND COMMUNICABLE
DISEASES TO DRIVE MARKET 40
4.2 BIOLOGICAL SAFETY CABINETS MARKET SHARE, BY TYPE, 2022 VS. 2027 41
FIGURE 12 CLASS II SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2027 41
4.3 BIOLOGICAL SAFETY CABINETS MARKET SHARE, BY END USER, 2022 VS. 2027 41
FIGURE 13 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES—LARGEST END USERS OF BIOLOGICAL SAFETY CABINETS 41
4.4 BIOLOGICAL SAFETY CABINETS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 42
FIGURE 14 ASIA PACIFIC REGION TO REGISTER HIGHEST GROWTH IN FORECAST PERIOD 42
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
FIGURE 15 BIOLOGICAL SAFETY CABINETS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 43
5.2.1 DRIVERS 43
5.2.1.1 Favorable regulations 43
5.2.1.2 Increased risk of pandemics and communicable diseases 44
5.2.1.3 Increasing number of R&D activities in pharmaceutical and biopharmaceutical companies 45
FIGURE 16 R&D SPENDING BY PHRMA MEMBER COMPANIES,
2001–2019 (USD BILLION) 45
TABLE 1 PHARMACEUTICAL R&D SPENDING, BY COMPANY,
2019 VS. 2026 (USD BILLION) 45
5.2.1.4 Rapid growth in biologics 46
FIGURE 17 TOTAL NUMBER OF NEW BIOLOGICS LICENSE APPLICATION APPROVALS, NDA APPROVALS, AND FILINGS (2005–2019) 47
TABLE 2 US: LIST OF BIOLOGICAL LICENSE APPLICATION APPROVALS, 2019 47
5.2.1.5 Growing concerns over cell culture contamination 48
5.2.2 RESTRAINTS 48
5.2.2.1 Alternative containment cabinets 48
5.2.2.2 High cost of biological safety cabinets 48
5.2.3 OPPORTUNITIES 49
5.2.3.1 Emerging markets offer lucrative growth opportunities 49
5.3 PRICING ANALYSIS 49
TABLE 3 PRICE OF BIOLOGICAL SAFETY CABINETS (2021) 49
5.4 PATENT ANALYSIS 51
FIGURE 18 PATENT ANALYSIS OF BIOLOGICAL SAFETY CABINETS MARKET 51
5.4.1 LIST OF MAJOR PATENTS 52
5.5 VALUE CHAIN ANALYSIS 52
FIGURE 19 VALUE CHAIN ANALYSIS OF BIOLOGICAL SAFETY CABINETS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 53
5.6 SUPPLY CHAIN ANALYSIS 54
FIGURE 20 BIOLOGICAL SAFETY CABINETS MARKET: SUPPLY CHAIN ANALYSIS 54
5.7 ECOSYSTEM/MARKET MAP 55
FIGURE 21 BIOLOGICAL SAFETY CABINETS MARKET: ECOSYSTEM/MARKET MAP 55
TABLE 4 BIOLOGICAL SAFETY CABINETS MARKET: ROLE IN ECOSYSTEM 55
5.8 PORTER’S FIVE FORCES ANALYSIS 56
TABLE 5 BIOLOGICAL SAFETY CABINETS MARKET: PORTER’S FIVE FORCES ANALYSIS 56
5.8.1 THREAT OF NEW ENTRANTS 56
5.8.2 THREAT OF SUBSTITUTES 56
5.8.3 BARGAINING POWER OF BUYERS 56
5.8.4 BARGAINING POWER OF SUPPLIERS 57
5.8.5 DEGREE OF COMPETITION 57
5.9 REGULATORY LANDSCAPE 57
TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 57
TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 58
TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 58
TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 59
TABLE 10 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 59
5.10 TRADE ANALYSIS 60
5.10.1 TRADE ANALYSIS FOR LABORATORY MACHINERY AND EQUIPMENT 60
TABLE 11 IMPORT DATA FOR LABORATORY MACHINERY AND EQUIPMENT, BY COUNTRY, 2017–2021 (USD MILLION) 60
TABLE 12 EXPORT DATA FOR LABORATORY MACHINERY AND EQUIPMENT, BY COUNTRY, 2017–2021 (USD MILLION) 60
5.11 TECHNOLOGY ANALYSIS 60
5.12 KEY CONFERENCES AND EVENTS IN 2022–2023 61
TABLE 13 BIOLOGICAL SAFETY CABINETS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 61
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 62
5.13.1 REVENUE SOURCES SHIFTING TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19 62
FIGURE 22 REVENUE SHIFT IN BIOLOGICAL SAFETY CABINETS MARKET 62
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 63
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 63
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOLOGICAL SAFETY CABINET PRODUCTS 63
TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOLOGICAL SAFETY CABINETS (%) 63
5.14.2 BUYING CRITERIA 64
FIGURE 24 KEY BUYING CRITERIA FOR BIOLOGICAL SAFETY CABINETS 64
TABLE 15 KEY BUYING CRITERIA FOR BIOLOGICAL SAFETY CABINETS 64
5.15 CASE STUDIES 65
5.15.1 CASE STUDY: LABORATORY BIOLOGICAL SAFETY CABINET (BSC) EXPLOSION 65
6 BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE 66
6.1 INTRODUCTION 67
TABLE 16 BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 67
TABLE 17 BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (THOUSAND UNITS) 67
6.2 CLASS I 68
6.2.1 GOVERNMENT INITIATIVES TO DRIVE MARKET 68
TABLE 18 CLASS I BIOLOGICAL SAFETY CABINETS MARKET, BY REGION,
2020–2027 (USD MILLION) 68
6.3 CLASS II 69
TABLE 19 CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 69
TABLE 20 CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY REGION,
2020–2027 (USD MILLION) 69
6.3.1 CLASS II TYPE A 70
6.3.1.1 Increased usage of Class II Type A biosafety cabinets in laboratories to support market growth 70
TABLE 21 CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY REGION,
2020–2027 (USD MILLION) 70
6.3.2 CLASS II TYPE B 71
6.3.2.1 Class II Type B cabinets used for volatile and toxic chemicals 71
TABLE 22 CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY REGION,
2020–2027 (USD MILLION) 71
6.4 CLASS III 71
6.4.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 71
TABLE 23 CLASS III BIOLOGICAL SAFETY CABINETS MARKET, BY REGION,
2020–2027 (USD MILLION) 72

7 BIOLOGICAL SAFETY CABINETS MARKET, BY END USER 73
7.1 INTRODUCTION 74
TABLE 24 BIOLOGICAL SAFETY CABINETS MARKET, BY END USER,
2020–2027 (USD MILLION) 74
7.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES 74
7.2.1 INCREASING R&D EXPENDITURE ENABLES COMPANIES TO INVEST IN HIGH-END BIOSAFETY CABINETS 74
TABLE 25 BIOLOGICAL SAFETY CABINETS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION) 75
7.3 DIAGNOSTIC AND TESTING LABORATORIES 75
7.3.1 RISING PREVALENCE OF DISEASES TO SUPPORT MARKET GROWTH 75
TABLE 26 BIOLOGICAL SAFETY CABINETS MARKET FOR DIAGNOSTIC AND TESTING LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 76
7.4 ACADEMIC RESEARCH INSTITUTES 76
7.4.1 INCREASING NUMBER OF RESEARCH ACTIVITIES AND RISING GOVERNMENT FUNDING FOR MEDICAL RESEARCH TO SUPPORT MARKET GROWTH 76
TABLE 27 BIOLOGICAL SAFETY CABINETS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 77
8 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION 78
8.1 INTRODUCTION 79
TABLE 28 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION,
2020–2027 (USD MILLION) 79
8.2 NORTH AMERICA 80
FIGURE 25 NORTH AMERICA: BIOLOGICAL SAFETY CABINETS MARKET SNAPSHOT 80
TABLE 29 NORTH AMERICA: BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 30 NORTH AMERICA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 81
TABLE 31 NORTH AMERICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 81
TABLE 32 NORTH AMERICA: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION) 82
8.2.1 US 82
8.2.1.1 Growth in biosimilars market to boost preclinical research 82
TABLE 33 US: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 83
TABLE 34 US: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 83
TABLE 35 US: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER,
2020–2027 (USD MILLION) 84
8.2.2 CANADA 84
8.2.2.1 Government support for R&D to support market growth 84
TABLE 36 CANADA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 85
TABLE 37 CANADA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 85
TABLE 38 CANADA: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER,
2020–2027 (USD MILLION) 85
8.3 EUROPE 86
TABLE 39 EUROPE: BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 86
TABLE 40 EUROPE: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 86
TABLE 41 EUROPE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 87
TABLE 42 EUROPE: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER,
2020–2027 (USD MILLION) 87
8.3.1 GERMANY 87
8.3.1.1 Increased funding and growth of research sector to drive market 87
TABLE 43 GERMANY: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 88
TABLE 44 GERMANY: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 45 GERMANY: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER,
2020–2027 (USD MILLION) 89
8.3.2 UK 89
8.3.2.1 Increasing awareness about safety in high-risk environments to propel market 89
TABLE 46 UK: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 90
TABLE 47 UK: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 90
TABLE 48 UK: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER,
2020–2027 (USD MILLION) 90
8.3.3 FRANCE 91
8.3.3.1 Growing healthcare industry to provide growth opportunities 91
TABLE 49 FRANCE: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 91
TABLE 50 FRANCE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 92
TABLE 51 FRANCE: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER,
2020–2027 (USD MILLION) 92
8.3.4 REST OF EUROPE 92
TABLE 52 REST OF EUROPE: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 93
TABLE 53 REST OF EUROPE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 94
TABLE 54 REST OF EUROPE: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER, 2020–2027 (USD MILLION) 94

8.4 ASIA PACIFIC 94
FIGURE 26 ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET SNAPSHOT 95
TABLE 55 ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 96
TABLE 56 ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 96
TABLE 57 ASIA PACIFIC: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 96
TABLE 58 ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER,
2020–2027 (USD MILLION) 97
8.4.1 JAPAN 97
8.4.1.1 Largest market for biological safety cabinets in Asia Pacific 97
TABLE 59 JAPAN: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 98
TABLE 60 JAPAN: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 98
TABLE 61 JAPAN: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER,
2020–2027 (USD MILLION) 98
8.4.2 CHINA 99
8.4.2.1 Government initiatives in drug development to support market growth 99
TABLE 62 CHINA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 100
TABLE 63 CHINA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 100
TABLE 64 CHINA: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER,
2020–2027 (USD MILLION) 100
8.4.3 INDIA 101
8.4.3.1 Growing pharmaceutical industry to drive market 101
TABLE 65 INDIA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 102
TABLE 66 INDIA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 102
TABLE 67 INDIA: BIOLOGICAL SAFETY CABINETS MARKET, BY END USER,
2020–2027 (USD MILLION) 102
8.4.4 REST OF ASIA PACIFIC 103
TABLE 68 REST OF ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 103
TABLE 69 REST OF ASIA PACIFIC: CLASS II BIOLOGICAL SAFETY CABINETS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 103
TABLE 70 REST OF ASIA PACIFIC: BIOLOGICAL SAFETY CABINETS MARKET,
BY END USER, 2020–2027 (USD MILLION) 104
8.5 LATIN AMERICA 104
8.5.1 FAVORABLE GOVERNMENT POLICIES AND INCREASING DEMAND FOR NEW DRUG MOLECULES—KEY FACTORS DRIVING MARKET 104
TABLE 71 LATIN AMERICA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE,
2020–2027 (USD MILLION) 105
TABLE 72 LATIN AMERICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 105
TABLE 73 LATIN AMERICA: BIOLOGICAL SAFETY CABINETS MARKET,
BY END USER, 2020–2027 (USD MILLION) 105
8.6 MIDDLE EAST AND AFRICA 106
8.6.1 INCREASING R&D INVESTMENTS AND FOCUS ON DEVELOPMENT OF NEW DRUGS TO DRIVE MARKET 106
TABLE 74 MIDDLE EAST AND AFRICA: BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 106
TABLE 75 MIDDLE EAST AND AFRICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 106
TABLE 76 MIDDLE EAST AND AFRICA: BIOLOGICAL SAFETY CABINETS MARKET,
BY END USER, 2020–2027 (USD MILLION) 107
9 COMPETITIVE LANDSCAPE 108
9.1 OVERVIEW 108
9.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 108
9.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOLOGICAL SAFETY CABINETS MARKET 108
TABLE 77 OVERVIEW OF STRATEGIES ADOPTED BY KEY BIOLOGICAL SAFETY CABINET MANUFACTURING COMPANIES 108
9.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 109
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN BIOLOGICAL SAFETY CABINETS MARKET 109
9.4 MARKET SHARE ANALYSIS 110
FIGURE 28 BIOLOGICAL SAFETY CABINETS MARKET SHARE, BY KEY PLAYER (2021) 110
TABLE 78 BIOLOGICAL SAFETY CABINETS MARKET: DEGREE OF COMPETITION 110
9.5 COMPANY EVALUATION QUADRANT 111
9.5.1 LIST OF EVALUATED VENDORS 111
9.5.2 STARS 111
9.5.3 EMERGING LEADERS 111
9.5.4 PERVASIVE PLAYERS 111
9.5.5 PARTICIPANTS 112
FIGURE 29 BIOLOGICAL SAFETY CABINETS MARKET:
COMPETITIVE LEADERSHIP MAPPING, 2021 112
9.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2021) 113
9.6.1 PROGRESSIVE COMPANIES 113
9.6.2 STARTING BLOCKS 113
9.6.3 RESPONSIVE COMPANIES 113
9.6.4 DYNAMIC COMPANIES 113
FIGURE 30 BIOLOGICAL SAFETY CABINETS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2021 114
9.7 COMPETITIVE BENCHMARKING 115
9.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS 115
FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN BIOLOGICAL SAFETY CABINETS MARKET 115
TABLE 79 BIOLOGICAL SAFETY CABINETS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 115
TABLE 80 PRODUCT FOOTPRINT OF COMPANIES 116
TABLE 81 REGIONAL FOOTPRINT OF COMPANIES 116
TABLE 82 BIOLOGICAL SAFETY CABINETS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 117
9.8 COMPETITIVE SCENARIO 117
9.8.1 PRODUCT LAUNCHES 117
TABLE 83 KEY PRODUCT LAUNCHES 117
10 COMPANY PROFILES 118
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1 KEY PLAYERS 118
10.1.1 THERMO FISHER SCIENTIFIC 118
TABLE 84 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 118
FIGURE 32 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021) 119
10.1.2 KEWAUNEE SCIENTIFIC 122
TABLE 85 KEWAUNEE SCIENTIFIC: BUSINESS OVERVIEW 122
FIGURE 33 KEWAUNEE SCIENTIFIC: COMPANY SNAPSHOT (2021) 123
10.1.3 LABCONCO 125
TABLE 86 LABCONCO: BUSINESS OVERVIEW 125
10.1.4 ESCO MICRO 127
TABLE 87 ESCO MICRO: BUSINESS OVERVIEW 127
10.1.5 THE BAKER COMPANY 129
TABLE 88 THE BAKER COMPANY: BUSINESS OVERVIEW 129
10.1.6 NUAIRE 131
TABLE 89 NUAIRE: BUSINESS OVERVIEW 131
10.1.7 GERMFREE LABORATORIES 133
TABLE 90 GERMFREE LABORATORIES: BUSINESS OVERVIEW 133
10.1.8 CRUMA 135
TABLE 91 CRUMA: BUSINESS OVERVIEW 135
10.1.9 AIR SCIENCE 136
TABLE 92 AIR SCIENCE: BUSINESS OVERVIEW 136
10.1.10 BERNER INTERNATIONAL 137
TABLE 93 BERNER INTERNATIONAL: BUSINESS OVERVIEW 137
10.1.11 AZBIL TELSTAR 139
TABLE 94 AZBIL TELSTAR: BUSINESS OVERVIEW 139
10.1.12 LABOGENE 140
TABLE 95 LABOGENE: BUSINESS OVERVIEW 140
10.1.13 BIOLAB SCIENTIFIC 142
TABLE 96 BIOLAB SCIENTIFIC: BUSINESS OVERVIEW 142
10.1.14 LAMSYSTEMS GMBH 144
TABLE 97 LAMSYSTEMS GMBH: BUSINESS OVERVIEW 144
10.1.15 FASTER S.R.L. 146
TABLE 98 FASTER S.R.L.: BUSINESS OVERVIEW 146
10.2 OTHER PLAYERS 148
10.2.1 MRC LABORATORY EQUIPMENT 148
TABLE 99 MRC LABORATORY EQUIPMENT: COMPANY OVERVIEW 148
10.2.2 NANBEI INSTRUMENT LIMITED 149
TABLE 100 NANBEI INSTRUMENT LIMITED: COMPANY OVERVIEW 149
10.2.3 THERMOLAB 150
TABLE 101 THERMOLAB: COMPANY OVERVIEW 150
10.2.4 LABMATE 150
TABLE 102 LABMATE: COMPANY OVERVIEW 150
10.2.5 TOPAIR SYSTEMS, INC. 151
TABLE 103 TOPAIR SYSTEMS, INC.: COMPANY OVERVIEW 151
10.2.6 ALBIAN GROUP 151
TABLE 104 ALBIAN GROUP: COMPANY OVERVIEW 151
10.2.7 THOMAS SCIENTIFIC 152
TABLE 105 THOMAS SCIENTIFIC: COMPANY OVERVIEW 152
10.2.8 ZHEJIANG FUXIA MEDICAL TECHNOLOGY CO., LTD. 152
TABLE 106 ZHEJIANG FUXIA MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 152
10.2.9 STERICOX 153
TABLE 107 STERICOX: COMPANY OVERVIEW 153
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX 154
11.1 DISCUSSION GUIDE 154
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 157
11.3 CUSTOMIZATION OPTIONS 159
11.4 RELATED REPORTS 159
11.5 AUTHOR DETAILS 160


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com